Young blood medicine maker for body rejuvenation.
Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.
Elevian’s founders have identified blood factors that regulate aging and stimulate the body’s natural repair and regeneration mechanisms. One well published example, GDF11, reduces age-related cardiac hypertrophy, accelerates skeletal muscle repair, and improves cognitive function in aged mammals. We are developing biotherapeutics that regulate these blood factors.
Visit website: https://www.elevian.com/
Elevian Blog Posts
Ambrosia Plasma relaunches - announces improvement in key ageing biomarkers
03-Feb-2020 The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch
People at Elevian
Investor, entrepreneurial community builder, advocate
Co-Founder and CEO at Elevian
Elevian raises $15M in preclinical work towards clinical antiaging
FierceBiotech - 24-Nov-2020
rGDF11 in clinic targets multiple age related disease therapiesRead more...